Docoh
Loading...

22 results

Filter options loading...
Top filers
Top filing types
Recent filing years
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
for PCS6422 and one for PCS499. Besides relying on patents, we also rely on trade secrets, proprietary know-how and continuing innovation to develop … of these trade secrets, proprietary know-how and any continuing innovation, in part, through confidentiality and proprietary information agreements. However
10-Q
2020 Q3
PCSA Processa Pharmaceuticals Inc
12 Nov 20
Quarterly report
4:01pm
) Aposense obtaining the approval of the Israel Innovation Authority for the consummation of the transactions contemplated by the agreement, which … to Nasdaq and (ii) Aposense obtaining the approval of the Israel Innovation Authority for the consummation of the transactions contemplated
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
obtaining the approval of the Israel Innovation Authority for the consummation of the transactions contemplated by the agreement, which approval was obtained … the biopharmaceutical industry is characterized by intense competition and rapid innovation, our competitors may be able to develop other compounds or drugs
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
Innovation Authority for the consummation of the transactions contemplated by the agreement, which approval was obtained on August 24, 2020. PCS11T … by intense competition and rapid innovation, our competitors may be able to develop other compounds or drugs that are able to achieve similar or better
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
closing of an equity financing and successful up-listing to Nasdaq and (ii) Aposense obtaining the approval of the Israel Innovation Authority … innovation, our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results than our product candidates
10-Q
2020 Q2
PCSA Processa Pharmaceuticals Inc
5 Aug 20
Quarterly report
3:32pm
the approval of the Israel Innovation Authority for the consummation of the transactions contemplated by the Aposense Agreement. PCS11T is a novel lipophilic … ): (i) our closing of an equity financing and successful up-listing to Nasdaq and (ii) Aposense obtaining the approval of the Israel Innovation
S-1/A
PCSA Processa Pharmaceuticals Inc
17 Jul 20
IPO registration (amended)
5:25pm
and successful up-listing to Nasdaq and (ii) Aposense obtaining the approval of the Israel Innovation Authority for the consummation … the biopharmaceutical industry is characterized by intense competition and rapid innovation, our competitors may be able to develop other compounds or drugs
8-K
EX-99.2
PCSA Processa Pharmaceuticals Inc
1 Jun 20
Entry into a Material Definitive Agreement
7:01am
obtaining the approval of the Israel Innovation Authority for the consummation of the transactions set forth in the agreement. Subject to the terms
10-K
2019 FY
PCSA Processa Pharmaceuticals Inc
5 Mar 20
Annual report
7:00pm
also rely on trade secrets, proprietary know-how and continuing innovation to develop and maintain our competitive position, especially when we do … innovation, in part, through confidentiality and proprietary information agreements. However, these agreements may not provide meaningful protection
S-1
PCSA Processa Pharmaceuticals Inc
13 Dec 19
IPO registration
5:32pm
by intense competition and rapid innovation, our competitors may be able to develop other compounds or drugs that are able to achieve similar or better … and continuing innovation to develop and maintain our competitive position, especially when we do not believe that patent protection is appropriate or can
10-K/A
2018 FY
PCSA Processa Pharmaceuticals Inc
5 Apr 19
Annual report (amended)
9:40pm
on trade secrets, proprietary know-how and continuing innovation to develop and maintain our competitive position, especially when we do not believe … that patent protection is appropriate or can be obtained. We seek protection of these trade secrets, proprietary know-how and any continuing innovation
10-K
2018 FY
PCSA Processa Pharmaceuticals Inc
28 Mar 19
Annual report
5:25pm
on trade secrets, proprietary know-how and continuing innovation to develop and maintain our competitive position, especially when we do not believe … that patent protection is appropriate or can be obtained. We seek protection of these trade secrets, proprietary know-how and any continuing innovation
424B3
PCSA Processa Pharmaceuticals Inc
9 Nov 18
Prospectus supplement
5:04pm
innovation, our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results than our product candidates … of patent term that may be available. We also rely on trade secrets, proprietary know-how and continuing innovation to develop and maintain our
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Oct 18
IPO registration (amended)
4:19pm
by intense competition and rapid innovation, our competitors may be able to develop other compounds or drugs that are able to achieve similar or better … and continuing innovation to develop and maintain our competitive position, especially when we do not believe that patent protection is appropriate or can
S-1/A
PCSA Processa Pharmaceuticals Inc
9 Oct 18
IPO registration (amended)
5:32pm
affecting the Processa business. Since the biopharmaceutical industry is characterized by intense competition and rapid innovation, our competitors … extension or adjustment of patent term that may be available. We also rely on trade secrets, proprietary know-how and continuing innovation to develop
S-1/A
PCSA Processa Pharmaceuticals Inc
13 Sep 18
IPO registration (amended)
8:00pm
the biopharmaceutical industry is characterized by intense competition and rapid innovation, our competitors may be able to develop other compounds or drugs … , proprietary know-how and continuing innovation to develop and maintain our competitive position, especially when we do not believe that patent protection
S-1
PCSA Processa Pharmaceuticals Inc
29 Jul 18
IPO registration
8:00pm
is characterized by intense competition and rapid innovation, our competitors may be able to develop other compounds or drugs that are able to achieve similar … for preparation and formulations. We also rely on trade secrets, proprietary know-how and continuing innovation to develop and maintain our competitive
10-K/A
2017 FY
PCSA Processa Pharmaceuticals Inc
16 Apr 18
Annual report (amended)
8:00pm
secrets, proprietary know-how and continuing innovation to develop and maintain our competitive position, especially when we do not believe that patent … protection is appropriate or can be obtained. We seek protection of these trade secrets, proprietary know-how and any continuing innovation, in part
10-K
2017 FY
PCSA Processa Pharmaceuticals Inc
15 Apr 18
Annual report
8:00pm
innovation to develop and maintain our competitive position, especially when we do not believe that patent protection is appropriate or can be obtained. We … seek protection of these trade secrets, proprietary know-how and any continuing innovation, in part, through confidentiality and proprietary
8-K/A
PCSA Processa Pharmaceuticals Inc
16 Oct 17
Entry into a Material Definitive Agreement
8:00pm
industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able … and formulations. We also rely on trade secrets, proprietary know-how and continuing innovation to develop and maintain our competitive position